Pregnancy Exposure Registry for Tysabri®
NCT00472992 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 376
Last updated 2014-08-11
Summary
The primary objective of the Registry was to evaluate the outcomes of pregnancy in women with Multiple Sclerosis (MS) or Crohn's Disease (CD) who were exposed to TYSABRI® at any time within 90 days prior to first day of Last Menstrual Period (LMP) or during pregnancy.
Conditions
- Crohn's Disease
- Prenatal Exposure
- Multiple Sclerosis
- Pregnancy
Sponsors & Collaborators
-
Elan Pharmaceuticals
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Medical Director · Biogen
Eligibility
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-01-31
- Primary Completion
- 2012-07-31
- Completion
- 2012-07-31
Countries
- United States
Study Locations
More Related Trials
-
Study on the Safety for the Newborn of the Use of Biologics During Pregnancy by Mothers Affected by Autoimmune Diseases
NCT04197232 ·Status: RECRUITING
-
Duke Autoimmunity in Pregnancy Registry
NCT00513591 ·Status: COMPLETED
-
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
NCT01196091 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
NCT06875960 ·Status: RECRUITING ·Phase: PHASE4
-
Anifrolumab Pregnancy Study
NCT07049653 ·Status: NOT_YET_RECRUITING
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542 ·Status: RECRUITING ·Phase: PHASE1
-
Rituximab Objective Outcome Measures Trial in SLE
NCT03054259 ·Status: UNKNOWN ·Phase: PHASE2
-
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
NCT00732940 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT06980805 ·Status: RECRUITING ·Phase: PHASE2
-
A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02
NCT00583362 ·Status: COMPLETED ·Phase: PHASE2
-
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT06044337 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
NCT05798117 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
NCT00657007 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare
NCT00423098 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus
NCT00657189 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
NCT01205438 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis
NCT00979654 ·Status: COMPLETED ·Phase: PHASE2
-
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT07175285 ·Status: RECRUITING
-
Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus
NCT01764594 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus
NCT00482989 ·Status: COMPLETED ·Phase: PHASE1
-
Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
NCT02106897 ·Status: COMPLETED ·Phase: PHASE1
-
To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus
NCT01300208 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.
NCT03958955 ·Status: TERMINATED ·Phase: PHASE2